These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

588 related articles for article (PubMed ID: 27981592)

  • 1. The ascending pathophysiology of cholestatic liver disease.
    Jansen PL; Ghallab A; Vartak N; Reif R; Schaap FG; Hampe J; Hengstler JG
    Hepatology; 2017 Feb; 65(2):722-738. PubMed ID: 27981592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis.
    Baghdasaryan A; Fuchs CD; Österreicher CH; Lemberger UJ; Halilbasic E; Påhlman I; Graffner H; Krones E; Fickert P; Wahlström A; Ståhlman M; Paumgartner G; Marschall HU; Trauner M
    J Hepatol; 2016 Mar; 64(3):674-81. PubMed ID: 26529078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrates and cholestasis.
    Ghonem NS; Assis DN; Boyer JL
    Hepatology; 2015 Aug; 62(2):635-43. PubMed ID: 25678132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug Therapies for Chronic Cholestatic Liver Diseases.
    Wagner M; Fickert P
    Annu Rev Pharmacol Toxicol; 2020 Jan; 60():503-527. PubMed ID: 31506007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel and emerging therapies for cholestatic liver diseases.
    Goldstein J; Levy C
    Liver Int; 2018 Sep; 38(9):1520-1535. PubMed ID: 29758112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of cholestatic disease in 2017.
    de Vries E; Beuers U
    Liver Int; 2017 Jan; 37 Suppl 1():123-129. PubMed ID: 28052628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis.
    Reich M; Spomer L; Klindt C; Fuchs K; Stindt J; Deutschmann K; Höhne J; Liaskou E; Hov JR; Karlsen TH; Beuers U; Verheij J; Ferreira-Gonzalez S; Hirschfield G; Forbes SJ; Schramm C; Esposito I; Nierhoff D; Fickert P; Fuchs CD; Trauner M; García-Beccaria M; Gabernet G; Nahnsen S; Mallm JP; Vogel M; Schoonjans K; Lautwein T; Köhrer K; Häussinger D; Luedde T; Heikenwalder M; Keitel V
    J Hepatol; 2021 Sep; 75(3):634-646. PubMed ID: 33872692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Aspects in the Management of Cholestatic Liver Diseases.
    Chazouillères O
    Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PPAR-Mediated Bile Acid Glucuronidation: Therapeutic Targets for the Treatment of Cholestatic Liver Diseases.
    Gallucci GM; Hayes CM; Boyer JL; Barbier O; Assis DN; Ghonem NS
    Cells; 2024 Aug; 13(15):. PubMed ID: 39120326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.
    Trauner M; Fickert P; Halilbasic E; Moustafa T
    Wien Med Wochenschr; 2008; 158(19-20):542-8. PubMed ID: 18998069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of bile acid synthesis as a tipping point in the disease course of primary sclerosing cholangitis.
    Braadland PR; Schneider KM; Bergquist A; Molinaro A; Lövgren-Sandblom A; Henricsson M; Karlsen TH; Vesterhus M; Trautwein C; Hov JR; Marschall HU
    JHEP Rep; 2022 Nov; 4(11):100561. PubMed ID: 36176935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unique bile acid profiles in the bile ducts of patients with primary sclerosing cholangitis.
    Kayashima A; Sujino T; Fukuhara S; Miyamoto K; Kubosawa Y; Ichikawa M; Kawasaki S; Takabayashi K; Iwasaki E; Kato M; Honda A; Kanai T; Nakamoto N
    Hepatol Commun; 2024 Jun; 8(6):. PubMed ID: 38780302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New therapies target the toxic consequences of cholestatic liver disease.
    Jansen PLM
    Expert Rev Gastroenterol Hepatol; 2018 Mar; 12(3):277-285. PubMed ID: 29310470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current pharmacotherapy for cholestatic liver disease.
    Carey EJ; Lindor KD
    Expert Opin Pharmacother; 2012 Dec; 13(17):2473-84. PubMed ID: 23094715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary sclerosing cholangitis.
    Rodriguez HJ; Bass NM
    Semin Gastrointest Dis; 2003 Oct; 14(4):189-98. PubMed ID: 14719769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chronic cholestatic liver diseases - Primary biliary cholangitis and Primary sclerosing cholangitis].
    Fejfar T; Vaňásek T; Hůlek P
    Vnitr Lek; 2020; 66(5):287-300. PubMed ID: 32942866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The current status of ursodeoxycholate in the treatment of chronic cholestatic liver disease.
    Luketic VA; Sanyal AJ
    Gastroenterologist; 1994 Mar; 2(1):74-9. PubMed ID: 8055235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cholestatic liver diseases].
    Thimme R; Opitz OG; Blum HE; Kreisel W
    Ther Umsch; 2004 Aug; 61(8):521-7. PubMed ID: 15457969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action.
    Poupon R
    Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S3-12. PubMed ID: 23141891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment.
    Stiehl A; Rudolph G; Sauer P; Theilmann L
    J Hepatol; 1995 Sep; 23(3):283-9. PubMed ID: 8550992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.